The purpose of this study is to assess the real-world effectiveness of deucravacitinib treatment in adults diagnosed with moderate-to-severe plaque psoriasis
≥18 years of age
Physician-reported diagnosis of moderate to severe plaque psoriasis
Be newly initiating deucravacitinib
Do not object to participate
Currently participating in or planning to participate in an interventional clinical trial
Previous treatment experience with deucravacitinib, including patients who received deucravacitinib as part of a blinded, randomized trial